The UK has undoubtedly experienced a wave of political and cultural change in recent weeks. We have seen a new Prime Minister assume leadership of the country, at the peak of one of the greatest economic crises in British history. On the 8 September, we also witnessed the tragic passing of Queen Elizabeth II, the news of which has reverberated across the globe. Our thoughts are with the Royal Family at this difficult time.

At a time of great need, the healthcare and pharma landscape continues to go at full throttle. Pfizer has revealed data showing that the Respiratory Syncytial Virus (RSV) vaccine is effective in older patients, burgeoning hopes for a first bivalent RSV vaccine candidate. China has approved the world’s first inhaled COVID-19 vaccine for emergency use, pioneering the potential use of needle-free products in the country and elsewhere.

As we transition out of summer and into the colder months, COVID-19 vaccine uptake in the UK is once again resuming urgency. Health officials are predicting a spike in COVID-19 and flu cases this autumn and winter, and millions across England and Scotland have been invited for their booster jab, with the elderly and most vulnerable individuals being prioritised. If eligible, be sure to receive vaccines for both to ensure maximum protection against severe disease – in accordance with expert advice.

That’s all from me, for now. We hope you enjoy reading our October issue. As usual – feel free to give us a follow on Twitter @Pharmafocus for regular exciting polls and the chance to have your say.

Lina Adams